As US COVID-19 cases surge even higher, with daily deaths passing the 2,000 mark for the first time since May, Pfizer and Germany's BioNTech announced they submitted an emergency use authorization (EUA) request for their vaccine, offering hope that the first doses will be available by the end of the year.And as the world passed 57 million cases, the World Health Organization (WHO) today recommended against using remdesivir for hospitalized patients.Pfizer and BioNTech apply for EUAIn their announcement today, the Pfizer and BioNTech said the EUA request to the Food and Drug Administration (FDA) for their mRNA vaccine candidate could mean it will be available for high-risk populations by the middle to end of December.